Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822896 | 0.84 | L3MBTL1 (0.41) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL28208469 | 0.80 | SMN1; SMN2 (0.51) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL3134348 | 0.76 | TSHR (0.41) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL29200488 | 0.76 | HSD17B10 (0.40) | TSHRALDH1A1LMNARAB9AMAPT | |
| Tetrahydrofuran SCHEMBL26646373 | 0.76 | TSHR (0.50) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL15531738 | 0.76 | TSHR (0.67) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL10787532 | 0.75 | ALDH1A1 (0.62) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL2963308 | 0.75 | TSHR (0.46) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL27752483 | 0.74 | ALDH1A1 (0.47) | TSHRALDH1A1LMNARAB9AMAPT | |
| SCHEMBL3129798 | 0.74 | TSHR (0.39) | TSHRALDH1A1LMNARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428473-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| CN-105732538-A | Cobicistat pamoic acid salt and preparation method therefor, drug composition and application | 杭州普晒医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-3009434-A1 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED | GILEAD SCIENCES, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2016-01-07 | — | — | US | disclosed |
| CN-104876888-A | Methods And Intermediates For Preparing Pharmaceutical Agents | GILEAD SCIENCES INC | 2015-09-02 | — | — | CN | disclosed |
| EP-2414325-B1 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED. | GILEAD SCIENCES INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9115100-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| CN-102438982-B | process for the preparation of cytochrome P450 monooxygenase inhibitors and intermediates involved | GILEAD SCIENCES INC | 2015-05-06 | — | — | CN | disclosed |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8853210-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| CN-102438982-A | Process for the preparation of cytochrome P450 monooxygenase inhibitors and intermediates involved | GILEAD SCIENCES INC | 2012-05-02 | — | — | CN | disclosed |
| EP-2414325-A2 | METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED | Gilead Sciences, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010115000-A2 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | TSHR 4139/4885ALDH1A1 160/4885LMNA 1297/4885 |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | TSHR 4139/4885ALDH1A1 160/4885LMNA 1297/4885 |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | TSHR 4139/4885ALDH1A1 160/4885LMNA 1297/4885 |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | TSHR 4139/4885ALDH1A1 160/4885LMNA 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.